Reflecting On The Consolidation Of PTPN, The Minister Of SOEs Hopes That The Indonesian Health Ecosystem Can Be Capai For Rp. 94 Trillion

Minister of SOEs Erick Thohir. (Photo: Doc. Antara)

BANDUNG - Minister of State-Owned Enterprises (BUMN) Erick Thohir hopes that the health ecosystem in Indonesia can reach IDR 94 trillion or 25 percent of the market share by 2027.

"Lastly, technology, we have aspirations in 2027. This is certainly an impetus for how this health ecosystem can reach IDR 94 trillion, which is 25 percent of the market share," said Erick Thohir while giving a speech at the launch and injection of the IndoVac Vaccine Prime Minister, quoted by Antara, Thursday, October 13.

Minister Erick said the encouragement so that the health ecosystem could reach IDR 94 trillion was an important thing for this country to do.

"This is important for us to do, as we experienced the incidence of cooking oil. When PTPN is consolidated, we only have 3 percent. So if we penetrate an unbalanced market, we are not strong. But with 25 percent strength, God willing, we can balance this," he said.

In his remarks, Minister Erick said that apart from food security and energy security, health security is one of the most important sectors for Indonesia in the future.

"Of course in a very current era, which is volatile in today's world. It is very important that Indonesia continues to be independent and even sovereign in filling its independence," he said.

Like today's event, namely the Launch of the IndoVac Vaccine which is the first step for the Indonesian people to be sovereign in the field of health resilience.

"How can we start producing the IndoVac Vaccine, but of course this is only the first step because we continue to encourage similar cooperation like yesterday to be signed in England with Profactor Pharma," he said.

He said the collaboration between Indonesia and the British pharmaceutical company, Profactor Pharma is related to hemofial vaccines or blood viscosity.

"So it's similar to what we did today. We cooperate with the R&D (research and development) but of course the license, brand and production are the same for us. With the Profactor, we sign the blood viscosity hemophilia vaccine," he said.